Literature DB >> 14688150

Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies.

E Garbe1, S Suissa.   

Abstract

A large number of observational studies, supported by animal and basic research studies, have shown a protective effect of hormone replacement therapy (HRT) on acute coronary outcomes. The recent large randomized Women's Health Initiative (WHI) study reported the opposite result, i.e. a small risk increase of 29% for acute coronary outcomes under estrogen-progestin treatment. Possible methodological reasons for these discrepancies are discussed. Despite randomization, the reported small increase in risk in the WHI study could be spurious because of differential unblinding of HRT users, which could have resulted in higher detection rates of otherwise clinically unrecognized acute myocardial infarction in these women. We show that altering diagnostic patterns because of unblinding could lower the crude rate ratio of 1.28 to 1.02. In the observational studies, the protective effect may have been exaggerated due to a healthy user bias and to the inappropriate choice of the reference group. Using an alternative reference group, the combined rate ratio of 0.67 was increased to 0.82. The diametrical effects of HRT on acute coronary outcomes found between the observational studies and the WHI Study may be a result not only of bias in the observational studies, but also of bias in the WHI Study.

Entities:  

Mesh:

Year:  2004        PMID: 14688150     DOI: 10.1093/humrep/deh022

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  14 in total

1.  The best type of trial.

Authors:  J A Chris Delaney
Journal:  CMAJ       Date:  2004-06-08       Impact factor: 8.262

Review 2.  Observational versus experimental studies: what's the evidence for a hierarchy?

Authors:  John Concato
Journal:  NeuroRx       Date:  2004-07

3.  Post menopausal hormones and measures of subclinical atherosclerosis: the multi-ethnic study of atherosclerosis.

Authors:  Eyal Shahar; Gregory L Burke; Mary Cushman; Susan R Heckbert; Pamela Ouyang; Moyses Szklo
Journal:  Prev Med       Date:  2007-12-27       Impact factor: 4.018

Review 4.  The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.

Authors:  Michael J Mauro; Catherine Davis; Teresa Zyczynski; H Jean Khoury
Journal:  Ther Adv Hematol       Date:  2015-02

5.  Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study.

Authors:  Mara A McAdams DeMarco; Janet W Maynard; Alan N Baer; Allan C Gelber; J Hunter Young; Alvaro Alonso; Josef Coresh
Journal:  Arthritis Rheum       Date:  2012-01

Review 6.  Cardiovascular consequences of hormone therapy in postmenopausal women: Messages to clinicians.

Authors:  O Ylikorkala; T Mikkola
Journal:  Reprod Med Biol       Date:  2005-03-07

7.  The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults.

Authors:  Amanda R Patrick; William H Shrank; Robert J Glynn; Daniel H Solomon; Colin R Dormuth; Jerry Avorn; Suzanne M Cadarette; Helen Mogun; M Alan Brookhart
Journal:  Value Health       Date:  2011-04-22       Impact factor: 5.725

Review 8.  Cardiovascular effects of noncardiovascular drugs.

Authors:  Satish R Raj; C Michael Stein; Pablo J Saavedra; Dan M Roden
Journal:  Circulation       Date:  2009-09-22       Impact factor: 29.690

9.  Statin adherence and risk of accidents: a cautionary tale.

Authors:  Colin R Dormuth; Amanda R Patrick; William H Shrank; James M Wright; Robert J Glynn; Jenny Sutherland; M Alan Brookhart
Journal:  Circulation       Date:  2009-04-06       Impact factor: 29.690

Review 10.  Midlife predictors of Alzheimer's disease.

Authors:  B B Bendlin; C M Carlsson; C E Gleason; S C Johnson; A Sodhi; C L Gallagher; L Puglielli; C D Engelman; M L Ries; G Xu; W Wharton; S Asthana
Journal:  Maturitas       Date:  2009-12-30       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.